Oct 8 (Reuters) - China's WuXi AppTec
said on Tuesday it was assessing options for continuing its cell and gene therapy manufacturing business, WuXi Advanced Therapies, but it has not entered any binding deals regarding the operations.
"There is uncertainty as to whether the company will eventually decide to dispose WuXi ATU, or take other options to retain WuXi ATU and execute other options so that such business can continue to operate," it said in an exchange filing.
(Reporting by Himanshi Akhand in Bengaluru; Editing by Alan Barona)
((Himanshi.Akhand@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.